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Introduction
Polycystic ovarian syndrome (PCOS), is the most 
recognized endocrine dysfunction affecting 5 to 10% 
women of reproductive age.1 While about 21% of women 
have PCOS,2 it impacts 15%-20% of infertile women.3
Insulin resistance (IR) is the most well-known 
characteristics of PCOS, represented in 85% of these 
women.4 An additional basic aspect of PCOS, high 
androgen levels, influences about 60% to 80% of PCOS 
women and is able to produce medical signs such as 
hirsutism, acne, and alopecia.5
The National Institutes of Health (NIH) suggested 
investigative criteria for PCOS requiring the concurrent 
existence of androgen excess (biochemical and/or 
clinical) and ovarian disorder.6 In 2003, the Rotterdam 
criteria define PCOS as the presence of at least 2 criteria 
from androgen excess, ovulatory disorder and polycystic 
ovarian morphology.7 The Androgen Excess Society 
(AES) reviewed PCOS investigative criteria that need to 
exits as androgen excess and menstrual disorder and/or 
PCO morphology.8
However, the actual incidence of PCOS in the society is 
the theme of a persisting discussion due to the specific 
sampling methodology used in each of the different 
studies plus study design limitations. Nevertheless, PCOS 
incidence based on the NIH criteria is appraised to be 
about 6% to 8%,9 with the application of the Rotterdam 
criteria, the incidence increased to 15% to 25%,10 while the 
implementation of the Androgen, AES recommendations 
puts PCOS incidence at about 10 to 15%.9
PCOS is a complex of symptoms of unknown cause and 
is defined as a heterogeneous dysfunction that results in 
Hyperandrogenism, existing evidence suggests that the 
ovarian theca cells are the real wellspring of the androgen 
generation and emission which assume a key part in the 
PCOS etiology.11
In addition, the hypothalamic-pituitary-ovarian (HPO) 
axis and IR may cause the PCOS. Changes in the 
sympathetic nervous system activity have also been 
proposed in the list of causes of this syndrome.12
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PCOS is related to the progress of severe endocrine, 
metabolic, cardiovascular, reproductive, and psychological 
problems.2
Due to its heterogeneous nature, an effective treatment 
of PCOS requires a consistent, multi-axes strategy with 
interdisciplinary experience, established on a strong 
evidence base to guide the unification of care. Many 
women with PCOS require long-lasting treatment that 
extends from lifestyle interference to precise medical 
or surgical methods. Medical treatments are effective 
although have several complications. Oral contraceptives 
are used as the first-line of treatment in PCOS, they 
minimize hirsutism and acne but have many negative 
effects on glucose tolerance, coagulability and fertility.13
Acupuncture, a treatment that goes back 3000–5000 
years of clinical practice, is a basic part of traditional 
Chinese medication and has turned out to be perceived in 
Western medicine more as a supplement or other choice 
to traditional treatments. Acupuncture therapy in female 
with PCOS and ovulatory disorder has been known to 
bring enduring useful results on the endocrine system 
and menstrual cycle, without complications.14
Laser acupuncture is considered to be an effective 
alternative to conventional needle acupuncture, is 
valuable in patients who are needle fearful, or can be used 
as a safe (e.g., virus C infection), non-invasive technique 
of treatment and a suitable method for stimulation of 
difficult points in the region of perineum or genitals.15 To 
our knowledge, no trial study has been done to address 
the therapeutic effect of laser acupoints on women with 
reproductive disorders. For that reason, the purpose of the 
present study is to assess the outcome of laser acupoints 
on female with PCOS.
Methods
Participants
Twenty-nine female with PCOS (n = 29) aged between 
19 and 23 years were recruited to the study in the 
gynecology department of the Kafrelsheikh General 
Hospital, Kafrelsheikh, Egypt. The evaluation procedures 
were explained to each participant. Prior to baseline 
measurements, 4 women dropped out, 2 because they 
wished to withdraw from the study and 2 were relocating 
to another city. Of the remaining women, 25 were 
haphazardly recruited for blood examinations.
Assessments were done at (1) baseline and (2) after 12 
weeks of intervention, from April to December 2016. 
Inclusion and Exclusion Criteria
The inclusion criteria were participants aged between 19 
and 23 years, body mass index (BMI) not exceeding 30 
kg/m2. PCOS women were assignable for randomization 
if they had clinical and/or biochemical signs of 
androgen excess (hirsutism or acne), together with one 
of the next symptoms: oligomenorrhea or amenorrhea 
(oligomenorrhea is generally defined as a cycle duration 
of more than 35 days while in amenorrhea the inter-cycle 
period exceeds 90 days), screened polycystic ovaries (≥12 
follicles with a 2-9 mm diameter on the ovary and/or 
ovarian volume >10 cm3) disclosed by ultrasonography in 
one or both ovaries, according to the AES.8
Exclusion criteria were: recognized endocrine causes 
of hyperandrogenemia, androgen-secreting neoplasm, 
Cushing syndrome, acromegaly, hyperprolactinemia, 
thyroid dysfunction, hypothalamic amenorrhea, ovarian 
insufficiency, congenital adrenal or ovarian hyperplasia 
and a drug-related condition.
Each woman was excluded from the study if she missed 
3 sessions.
Design
This is a randomized controlled trial with blinding of 
participants and examiners. As participants were blinded 
to the knowledge of the group they would create, since 
the participant selected a numbered envelope, which did 
not let the participant to know the group that she would 
comprise (study or control). Thus, the PCOS participants 
were randomized into blocks and allocated, using a 
simple, non-probability sampling method, to either the 
study group (SG; n = 13), treated by laser acupoints or the 
control group (CG; n = 12), which were treated by placebo 
laser acupoints. 
Sample-Size Calculation
Assuming a 30% improvement in blood hormonal levels of 
PCOS women in the study group, based on a sample with 
the power size estimation of the study beta of 80%, and to 
detect the effect size of difference 5%, with a significance 
level of P < 0.05, 10 participants were required.
Intervention
The condition of PCOS women randomized to the group 
treated by laser acupoints for 3 months was assessed at 
baseline and after 12 weeks (end of intervention), during 
which time they undertook two sessions per week during 
first 2 weeks, one session/week through 4 weeks, and one 
session every seconds week for 6 weeks, in a total of 11 
sessions through 12 weeks.16
Acupoints selection was based on previous studies14 and 
clinical trials treating PCOS women.
Laser acupoints were selected according to innervations 
of the ovaries (Th12–L2, S2–S4) to modulate HPO and the 
hypothalamic-pituitary-adrenal (HPA) axes to support 
hormonal balance17 (Table 1).
An infrared laser (Acu-Lase, Petrolaser, Russia) with 830 
nm wavelength, 10 mW power output and 0.5 J energy 
was applied 60 seconds for each acupoint. The head of the 
machine was used perpendicularly, with direct contact to 
each point.
The physiotherapist responsible for performing laser 
acupoints had experience in acupuncture within women’s 
health. All participants in the intervention group were 
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given an info brochure, that included advice on a healthy 
diet as a low-carbohydrate and high-protein diet,18 high 
dietary fiber, and less saturated fat,19 were instructed to 
engage in aerobic exercise, fast walking for at least 30 - 45 
min, 3 days a week.16 Women in the control group were 
treated by placebo laser acupoints with the same pieces of 
advice on healthy diet and exercise as in the intervention 
group.
Neither group was undergoing physiotherapy or any 
other treatment during the intervention period. 
Outcome Measures
The whole analyses were performed at a certified 
laboratory at the Department of Clinical Chemistry, 
Kafrelsheikh General Hospital. Blood tests included 
serum free testosterone (FT), serum total testosterone 
(TT), luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH), LH/FSH ratio, anti-Müllerian hormone 
(AMH) and insulin sensitivity was calculated with a 
homeostasis model assessment of insulin resistance 
(HOMA-IR).20 Blood samples were taken independently 
on day 2 or 3 of the follicular phase of the menstrual 
cycle because the majority of the participants had ovarian 
dysfunction.
All the biochemical checkups were done for both groups 
(SG and CG) at (1) baseline and (2) after 12 weeks of 
intervention.
Data Analysis
The collected data were categorized, tabulated and 
analyzed using descriptive statistics in terms of mean 
± standard deviation, frequency, and percentage. The 
paired t test was used to analyze and compare blood 
hormonal levels within each group (SG or CG) before and 
after the intervention. The independent t test was carried 
out to evaluate differences between both groups (SG and 
CG) before and after the intervention. A P value <0.05 
was considered statistically significant. Data analysis was 
done using SPSS software version 16.
Results
Out of the 34 women originally contacted at their first 
visit, 29 achieved the inclusion criteria. Of these, 4 
withdrew from the study and 25 PCOS women (aged 20 
± 1.2 years) were randomly allocated into the study group 
(SG; n = 13) or a control group (CG; n = 12) (Figure 1).
PCOS phenotype according to AES8 was as follows: in 
the study group, 6 (46.1%) had androgen excess and 
ovulatory dysfunction, 4 (30.8%) had androgen excess 
and PCO morphology, and 3 (23.1%) had androgen 
excess, ovulatory dysfunction, and PCO morphology; 
in the control group, 5 (41.7%) had androgen excess and 
ovulatory dysfunction, 5 (41.7%) had androgen excess 
and PCO morphology, and 2 (16.6%) had androgen 
excess, ovulatory dysfunction, and PCO morphology.
Baseline characteristics of the participants are 
summarized in Table 2. There were no statistically 
significant differences between both groups (SG and CG) 
in any of these characteristics (P > 0.05).
The mean application of laser acupoints sessions in the 
study group was 10 ± 0.1 out of 11 possible sessions. 
Ten out of the 13 women in the study group (76.9 %) 
performed at least 9 (81.8%) of weekly sessions. No 
hazards were re ported by the participants.
Within-group analyses revealed that BMI, blood 
hormonal levels, and IR were significantly decreased 
(P < 0.05), with no significant change in FSH (P > 0.05) in 
the 2 groups (Tables 3 and 4) (Figures 2 and 3).
Between-group analyses at the end of intervention 
revealed that most outcomes measures were significantly 
decreased (P < 0.05) in SG contrasted with CG, with no 
significant changes in FSH and BMI (P > 0.05) between 
the two groups (Table 5) (Figure 4).
Menstrual and ovulation frequencies were as follows: in the 
study group, 9 of 13 (69.23 %) were oligo-or amenorrhoeic 
before the intervention and 6 (66.7 %) reported 3 regular 
menses throughout the study: in the control group, 7 
of 12 (58.33 %) were oligo-or amenorrhoeic before the 
intervention and 5 (41.67 %) reported 3 regular menses 
throughout the study.
Discussion
The purpose of our study was to investigate the impact 
of treatment with laser acupoints on PCOS women. 
The progress in the different outcomes was evaluated 
by comparing the post-treatment results with those at 
the pretreatment, evaluating improvement within group 
separately. In addition, we compared the results between 
both groups.
This study showed that, within groups, we have found 
an enhancement in all measures at the end of the 
intervention, with no significant variation within the two 
Table 1. Laser Acupoints With Anatomical Position and Innervation
Point Location Innervation
Ren4 (Unilateral) On the midline, 3 cun lower to the umbilicus. Anterior cutaneous nerve of the subcostal nerve
Ren5 (Unilateral On the midline, 2 cun lower to the umbilicus. Anterior cutaneous branch  of the 11th  intercostal nerve
St29 (Bilateral) 4 cun under the umbilicus, 2 cun sideways to the midline. The iliohypogastric nerve (Th6-12).
Sp6 (Bilateral)
3 cun higher than the tip of the medial malleolus on the 
posterior margin of the tibia.
Superficially, the medial crural cutaneous nerve; deeper, 
in the posterior aspect, the tibial nerve (L4-5, S1-2).
Cun is the estimation of one “body inch” utilized to find acupuncture points. Estimation is constantly taken from the patient’s hand. The breadth of 
the thumb is 1 cun, breadth of 2 fingers is 1.5 cun, 4 fingers are 3 cun.
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groups regarding the FSH level.
PCOS women demonstrate a state of IR and 
hyperinsulinemia, thus, androgen generation can be 
overstimulated. This is mainly obvious in the existence 
of increased BMI.21 Hyperinsulinemia contributes to 
the unusual gonadotropin-releasing hormone (GnRH) 
secretion, in spite of the fact that the mechanism is not 
clear.22
An increase in serum LH levels is conflictingly found in 
5 
 
The collected data were categorized, tabulated and analyzed using descriptive statistics 
in terms of mean  standard deviation, frequency, and percentage. The paired t test was 
used to analyze and compare blood hormonal levels within each group (SG or CG) 
before and after the intervention. The independent t test was carried out to evaluate 
differences between both groups (SG and CG) before and after the intervention. A P 
value <0.05 was considered statistically significant. Data analysis was done using SPSS 
software version 16. 
 
Results 
Out of the 34 women originally contacted at their first visit, 29 achieved the inclusion 
criteria.  Of these, 4 withdrew from the study and 25 PCOS women (aged 20 ± 1.2 
years) were randomly allocated into the study group (SG; n=13) or a control group (CG; 
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Table 2. Baseline Characteristics of PCOS Women in the 2 groups







Age (y) 20.2±0.3 19.8±0.8 0.52
BMI(kg/m2) 27.15±2.1 26.9±1.7 0.61
FT, ng/dL 2.1±0.1 1.9 ±0.3 0.19
TT, ng/dL 69.5±2.1 66.3±1.3 0.20
LH, mIU/mL 10.1±1.3 11.3±0.3 0.63
FSH, mIU/mL 4.9±0.8 5.0±0.2 0.70
LH/FSH ratio 2.4±0.3 2.5±0.5 0.81
AMH, ng/mL 12.0±1.9 13.3±1.4 0.31
HOMA-IR 2.9±1.3 2.5±1.4 0.21
HOMA-IR, the indicator of which was considered according to the rule: 
[fasting plasma glucose (mg/dL) × fasting plasma insulin concentration 
(mU/L)]/405.
PCOS women, due to a G RH increase in the sufficiency 
and recurrence of pulsatile LH secretory pattern.23 Levels 
of FSH in PCOS appear to be within the lower follicular 
range, and response to GnRH is relatively similar to 
ovulatory controls.24 All these factors increase the LH/FSH 
ratio; the most obvious neuroendocrine characteristic 
regulating abnormal ovarian follicle maturity in PCOS 
is increased LH pulsatility regarding both frequency and 
amplitude, with relatively low FSH secretion.25 On account 
of an increased LH/ FSH ratio, the ovarian granulosa cells 
cannot aromatize the androgens to estrogens, which leads 
to diminished estrogen levels and ensuing anovulation26 
that are consistent with our results.
AMH levels in PCOS women emphatically correspond 
with antral follicle number and androgen levels, are 
increased 2-3 fold,27 and are lessened in parallel with a 
decrease of androgen level in our study.
The most excellent therapeutic approach for weight 
reduction in obese PCOS women has not yet been 
explored. Lifestyle changes, mainly a caloric restriction 
diet alone or with exercises,28 are suggested as a first-line 
of treatment in the overweight and obese PCOS women.29
Dietetic-induced weight reduction enhances IR and 
hyperinsulinemia. Both fasting and glucose-stimulated 
insulin are predisposed to significantly diminish after a 
weight reduction by about 5%–10%.28
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A significant decrease of total and free testosterone levels 
after dietetic-induced weight reduction was affirmed 
and agreed with our study. Additionally, controlled 
trials have obtained similar outcomes, despite the fact 
that others did not report any impact. Weight reduction 
can be followed by a significant improvement in SHBG 
concentration, which is steady with a diminishment of the 
free androgen.28,30
In spite of the fact that exercise in overweight or obese 
PCOS women enhances insulin sensitivity, the impact 
of exercise is by all accounts through mechanisms 
inconsequential to weight reduction31; exercise can 
improve rates of glucose clearance and the skeletal muscle 
sensitivity take-up to insulin.32
Table 3. Comparison of the Mean of Outcomes Measures Within Study 
Group After 12 Weeks of Intervention
Variables
Mean ± SD Outcomes Measures
Study Group (n=11)
Baseline End of Intervention  P Value
BMI (kg/m2) 27.15±2.1 25.6±0.1 0.04
FF, ng/dL 2.1±0.1 1.09±0.1 0.02
TT, ng/dL 69.5±2.1 60.0±0.1 0.04
LH, mIU/mL 10.1±1.3 6.9±0.9 0.01
FSH, mIU/mL 4.9±0.8 4.8±0.6 0.52
LH/FSH ratio 2.4±0.3 1.3±0.0 0.02
AMH, ng/mL 12.0±1.9 8.5±1.3 0.01
HOMA-IR 2.9±1.3 1.9±1.5 0.01
Table 4. Comparison of the Mean of Outcomes Measures Within 
Control Group After 12 Weeks of Intervention
Variables
Mean ± SD Outcomes Measures
Control Group (n=10)
Baseline End of Intervention  P Value
BMI (kg/m2) 26.9 ±1.7 25.0 ±1.2 0.04
FF, ng/dL 1.9 ±0.3 1.5±0.05 0.01
TT, ng/dL 66.3±1.3 63.0±1.9 0.05
LH, mIU/mL 11.3±0.3 9.9±0.2 0.02
FSH, mIU/mL 5.0±0.2 4.8±0.4 0.45
LH/FSH ratio 2.5±0.5 2.0±0.6 0.03
AMH, ng/mL 13.3±1.4 11.9±0.9 0.04
HOMA-IR 2.5±1.4 2.1±0.7 0.05
Table 5. Comparison of Mean Outcomes Measures Between the 2 
Groups After 12 Weeks of Intervention
Variables
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LH, mIU/mL 6.9±0.9 9.9±0.2 0.02
FSH, mIU/mL 4.8±0.6 4.8±0.4 0.67
LH/FSH ratio 1.3±0.0 2.0±0.6 0.03
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In the present study, diminished HOMA, IR is an 
indication of progress in insulin sensitivity and decreased 
IR.
Chronic anovulation is a common characteristic f PCOS 
women, and the return of ordinary ovulatory function 
represents the main target to be accomplished for PCOS 
women complaining of ovarian dysfunction and/or 
infertility.
In our study, the menstrual pattern was as follows: 6 of 9 
reported 3 regular menses in the study group, with 5 of 7 
reported 3 regular menses in the control group. 
The mechanisms responsible for the beneficial outcome 
of weight reduction on menses changes and fertility likely 
rely upon the parallel reduction of both hyperinsulinemia 
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and hyperandrogenemia. Evidence exists that dietetic-
initiated weight reduction may enhance both menstrual 
variations from the norm and spontaneous ovulation in 
the larger part of PCOS women.33 Unexpectedly, it ought 
to be noted that obtainable information on the results of 
weight reduction on menses variations from the norm 
among obese PCOS women have frequently been obtained 
in uncontrolled trials, in studies including a control group 
who neglected to complete the study protocol, and even 
with insignificant (5% of baseline) weight reduction 
throughout treatment.34
Our data suggest improved outcomes for PCOS 
women treated with laser acupoints (SG) compared 
with those treated with placebo laser acupoints (CG). 
The mechanism, by which laser influences the insulin 
sensitivity, is still unknown. Notwithstanding, there are 
numerous physiological proposals that may clarify the 
change in insulin sensitivity.35 It has also been found that 
women with PCOS have low-grade inflammation, which 
might be a reason for IR.
Use of laser reduces the level of cytokines discharged from 
white blood cells (inflammatory response)36; cytokines 
such as TNF-alpha, IL-1 beta, and IL-8 proteins contribute 
to IR and atherosclerosis.37
Utilization of laser stimulates the respiratory electron 
transport chain, resulting in (1) changes in the reduction/
oxidation status of the mitochondria which leads to 
enhanced ATP synthesis (Krebs cycle), (2) activation 
of sodium/potassium pump modifies cell membrane 
permeability to the flow of calcium.38
The enhancement of ions transportation over the cell 
membrane, that occur in instances of hyperinsulinemia 
or IR, may enhance the insulin action on the cells and 
contribute to lessening the insulin level.39
These acupoints compare to particular regions on the 
body surface, which exhibit high electrical conductance 
on account of the existence of high density of gap junctions 
alongside cell margins. They go about as convergent 
points for electromagnetic fields. A high metabolic rate, 
high temperature, and calcium ion concentration are 
likewise seen at these points.40 
Laser is a type of electromagnetic radiation used to 
stimulate acupuncture points using the same principles of 
point determination as for needle acupuncture.
An explanation for the changes for PCOS women in the 
SG compared with those in the CG is that laser acupoint 
placed in the identical innervation part as the ovary 
reduces sympathetic activity that prompts diminished 
discharge of ovarian androgens. In parallel, the action of 
higher centers is modulated by the discharge of opioids, 
specifically B-endorphin which thusly influence GnRH 
secretion and the menstrual cycle. Animal studies have 
exposed that acupuncture therapy standardized GnRH 
emission and influenced peripheral GnRH levels.41 In 
women with PCOS, there is an increased sympathetic 
nerve activity and an increased B-endorphin secretion. 
Laser acupoint diminishes central B-endorphin, 
causing a decreased sympathetic tone, decreased LH 
and release of B-endorphin into the circulation system. 
Different investigators have exposed that, acupuncture 
likewise affected serum levels of LH, FSH, E2, and P in 
typically ovulatory or anovulatory women.42 Another 
study by Stener-Victorin et al14 assessed the impact of 
electroacupuncture (EA) for induction of ovulation on 24 
PCOS women. The proportion of menstrual cycles in all 
participants appeared to be enhanced by 15%-66% up to 3 
months post-treatment. The BMI, waist/hip circumference 
ratio, LH/FSH ratio, serum testosterone concentrations 
and the B-endorphin concentration diminished 
significantly after treatment, showing that acupuncture 
could be considered as an option or subordinate to 
pharmacological induction of ovulation. Through its 
central sympathetic-inhibitory impact, acupuncture 
may diminish uterine artery resistance and in this way, 
improve uterine blood flow.43 The peripheral influence 
of acupuncture in enhancing uterine blood flow and 
hereafter endometrial thickness also gives encouraging 
information in regards to its potential positive effect on 
implantation and enhancement of infertility treatment 
outcomes. As of late, skin light contact has appeared 
to stimulate mechanoreceptors with slow conducting 
unmyelinated (C) afferents which regulate activity in the 
central nervous system44 of both groups in our study.
Limitations of our study were changes in the factors: 
psycho-physiological, social and cultural level of PCOS 
participants, which may or may not have had an impact 
on the outcomes, but until now have not been clarified in 
the literature. Future scientific studies on the effectiveness 
of various physical therapy modalities as ultrasonic 
acupoints in the treatment of PCOS women is really 
advised.
Conclusion
Based on the present analysis, laser acupoints stand for an 
efficient and safe form of acupuncture for the treatment 
of PCOS women and could be considered as a viable 
alternative or complement to pharmacological induction 
of ovulation.
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